Genome&Company
Develops microbiome drugs and novel immune checkpoint inhibitors for immuno-oncology.
314130 | KO
Overview
Corporate Details
- ISIN(s):
- KR7314130006
- LEI:
- Country:
- South Korea
- Address:
- 경기도 수원시 영통구 창룡대로256번길 50 7층, 8층, 수원시
- Website:
- http://genomecom.co.kr/
- Sector:
- Manufacturing
Description
Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-28 00:00 |
임시주주총회결과
|
Korean | 4.7 KB | ||
| 2023-12-28 00:00 |
본점소재지변경
|
Korean | 5.1 KB | ||
| 2023-12-22 00:00 |
기타경영사항(자율공시)(전환우선주의 보통주 전환청구)
|
Korean | 10.2 KB | ||
| 2023-12-15 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2023-12-15 00:00 |
기타경영사항(자율공시)(전환우선주의 보통주 전환청구)
|
Korean | 8.9 KB | ||
| 2023-12-13 00:00 |
주주총회소집공고
|
Korean | 72.4 KB | ||
| 2023-12-08 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 92.8 KB | ||
| 2023-12-08 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.7 KB | ||
| 2023-12-08 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 81.9 KB | ||
| 2023-12-08 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.7 KB | ||
| 2023-12-04 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청)(마이크로바이옴 면역항암 치료제 GEN-001의 위 또는 위식도 접합부 선암종 환자 …
|
Korean | 14.7 KB | ||
| 2023-12-04 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인)(마이크로바이옴 면역항암 치료제 GEN-001의 위 또는 위식도 접합부 선암종 환자 대상…
|
Korean | 15.9 KB | ||
| 2023-12-04 00:00 |
[기재정정]투자판단관련주요경영사항(마이크로바이옴 면역항암 치료제 GEN-001의 담도암 환자 대상 국내 제2상 임상시험계획 (IND) 변경승인…
|
Korean | 17.3 KB | ||
| 2023-12-04 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인)(진행성 불응성 담도암 환자를 대상으로 펨브롤리주맙과 병용 투여 시 GEN-001의 안전…
|
Korean | 14.9 KB | ||
| 2023-11-17 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.2 KB |
Automate Your Workflow. Get a real-time feed of all Genome&Company filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Genome&Company
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Genome&Company via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
